MXPA04007192A - Uso de melagatrana para la manufactura de un medicamento para el tratamiento de diabetes mellitus tipo i. - Google Patents
Uso de melagatrana para la manufactura de un medicamento para el tratamiento de diabetes mellitus tipo i.Info
- Publication number
- MXPA04007192A MXPA04007192A MXPA04007192A MXPA04007192A MXPA04007192A MX PA04007192 A MXPA04007192 A MX PA04007192A MX PA04007192 A MXPA04007192 A MX PA04007192A MX PA04007192 A MXPA04007192 A MX PA04007192A MX PA04007192 A MXPA04007192 A MX PA04007192A
- Authority
- MX
- Mexico
- Prior art keywords
- melagatran
- pharmaceutically acceptable
- cells
- acceptable derivative
- treatment
- Prior art date
Links
- DKWNMCUOEDMMIN-PKOBYXMFSA-N melagatran Chemical compound C1=CC(C(=N)N)=CC=C1CNC(=O)[C@H]1N(C(=O)[C@H](NCC(O)=O)C2CCCCC2)CC1 DKWNMCUOEDMMIN-PKOBYXMFSA-N 0.000 title claims abstract description 77
- 229960002137 melagatran Drugs 0.000 title claims abstract description 74
- 238000011282 treatment Methods 0.000 title claims abstract description 32
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 title claims abstract description 18
- 239000003814 drug Substances 0.000 title claims abstract description 13
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 13
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 54
- 238000000034 method Methods 0.000 claims description 38
- 210000004027 cell Anatomy 0.000 claims description 37
- 210000004369 blood Anatomy 0.000 claims description 30
- 239000008280 blood Substances 0.000 claims description 30
- 238000002054 transplantation Methods 0.000 claims description 28
- 102000004877 Insulin Human genes 0.000 claims description 27
- 108090001061 Insulin Proteins 0.000 claims description 27
- 229940125396 insulin Drugs 0.000 claims description 27
- 210000004153 islets of langerhan Anatomy 0.000 claims description 22
- 206010012601 diabetes mellitus Diseases 0.000 claims description 13
- 239000000651 prodrug Substances 0.000 claims description 13
- 229940002612 prodrug Drugs 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 10
- 238000009472 formulation Methods 0.000 claims description 8
- 239000002243 precursor Substances 0.000 claims description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 210000000130 stem cell Anatomy 0.000 claims description 6
- 206010061218 Inflammation Diseases 0.000 claims description 5
- 230000004054 inflammatory process Effects 0.000 claims description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 210000004185 liver Anatomy 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 3
- 239000000306 component Substances 0.000 description 16
- 230000010412 perfusion Effects 0.000 description 14
- 210000001772 blood platelet Anatomy 0.000 description 12
- 239000012634 fragment Substances 0.000 description 12
- 102100036154 Platelet basic protein Human genes 0.000 description 10
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 229960002897 heparin Drugs 0.000 description 8
- 229920000669 heparin Polymers 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 101800003265 Beta-thromboglobulin Proteins 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- 230000000295 complement effect Effects 0.000 description 6
- 210000000496 pancreas Anatomy 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 108010094028 Prothrombin Proteins 0.000 description 5
- 102100027378 Prothrombin Human genes 0.000 description 5
- 239000004019 antithrombin Substances 0.000 description 5
- 230000015271 coagulation Effects 0.000 description 5
- 238000005345 coagulation Methods 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 210000001616 monocyte Anatomy 0.000 description 5
- 229940039716 prothrombin Drugs 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 101000947178 Homo sapiens Platelet basic protein Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000004154 complement system Effects 0.000 description 4
- 238000011532 immunohistochemical staining Methods 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000004820 blood count Methods 0.000 description 3
- 230000024203 complement activation Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000003714 granulocyte Anatomy 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 2
- 238000011891 EIA kit Methods 0.000 description 2
- 101001078143 Homo sapiens Integrin alpha-IIb Proteins 0.000 description 2
- 102100025306 Integrin alpha-IIb Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 108010022999 Serine Proteases Proteins 0.000 description 2
- 102000012479 Serine Proteases Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 101000712605 Theromyzon tessulatum Theromin Proteins 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 229940122388 Thrombin inhibitor Drugs 0.000 description 2
- 229920000392 Zymosan Polymers 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 208000033679 diabetic kidney disease Diseases 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 210000003240 portal vein Anatomy 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 239000003868 thrombin inhibitor Substances 0.000 description 2
- 241001631457 Cannula Species 0.000 description 1
- 108010077840 Complement C3a Proteins 0.000 description 1
- 229940124073 Complement inhibitor Drugs 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010067035 Pancrelipase Proteins 0.000 description 1
- 208000035965 Postoperative Complications Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000000516 activation analysis Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- RIIWUGSYXOBDMC-UHFFFAOYSA-N benzene-1,2-diamine;hydron;dichloride Chemical compound Cl.Cl.NC1=CC=CC=C1N RIIWUGSYXOBDMC-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 239000004074 complement inhibitor Substances 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 238000005213 imbibition Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000001019 normoglycemic effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 238000009527 percussion Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000010118 platelet activation Effects 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000031915 positive regulation of coagulation Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/39—Pancreas; Islets of Langerhans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0200198A SE0200198D0 (sv) | 2002-01-23 | 2002-01-23 | New use |
| PCT/SE2003/000087 WO2003061682A1 (en) | 2002-01-23 | 2003-01-21 | The use of melagatran for the manufacture of a medicament for the treatment of type 1 diabetes mellitus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA04007192A true MXPA04007192A (es) | 2004-10-29 |
Family
ID=20286751
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA04007192A MXPA04007192A (es) | 2002-01-23 | 2003-01-21 | Uso de melagatrana para la manufactura de un medicamento para el tratamiento de diabetes mellitus tipo i. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US7045502B2 (https=) |
| EP (1) | EP1469874A1 (https=) |
| JP (1) | JP2005516035A (https=) |
| KR (1) | KR20040075096A (https=) |
| CN (1) | CN100430089C (https=) |
| BR (1) | BR0306798A (https=) |
| CA (1) | CA2472241A1 (https=) |
| IL (1) | IL162853A0 (https=) |
| MX (1) | MXPA04007192A (https=) |
| NO (1) | NO20043483L (https=) |
| NZ (1) | NZ533749A (https=) |
| SE (1) | SE0200198D0 (https=) |
| WO (1) | WO2003061682A1 (https=) |
| ZA (1) | ZA200405342B (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0200198D0 (sv) * | 2002-01-23 | 2002-01-23 | Astrazeneca Ab | New use |
| JP6155187B2 (ja) | 2010-03-30 | 2017-06-28 | ヴァーセオン コーポレイション | トロンビンの阻害剤としての多置換芳香族化合物 |
| HK1214252A1 (zh) | 2013-03-15 | 2016-07-22 | Verseon Corporation | 作為凝血酶抑制劑的鹵代吡唑 |
| CN110179795A (zh) | 2013-03-15 | 2019-08-30 | 维颂公司 | 作为丝氨酸蛋白酶抑制剂的多取代芳族化合物的制药用途 |
| US10189810B2 (en) | 2014-09-17 | 2019-01-29 | Verseon Corporation | Pyrazolyl-substituted pyridone compounds as serine protease inhibitors |
| CN107405333A (zh) | 2015-02-27 | 2017-11-28 | 维颂公司 | 作为丝氨酸蛋白酶抑制剂的被取代的吡唑化合物 |
| CN113164765B (zh) | 2018-07-13 | 2026-03-20 | 维颂国际公司 | 凝血酶抑制剂、制剂及其用途 |
| JP2024535677A (ja) | 2021-08-11 | 2024-10-02 | サナ バイオテクノロジー，インコーポレイテッド | 即時血液媒介性炎症反応を減少させるための同種細胞療法を目的とした遺伝子改変細胞 |
| KR20240155390A (ko) | 2022-02-17 | 2024-10-28 | 사나 바이오테크놀로지, 인크. | 조작된 cd47 단백질 및 이의 용도 |
| WO2024229302A1 (en) | 2023-05-03 | 2024-11-07 | Sana Biotechnology, Inc. | Methods of dosing and administration of engineered islet cells |
| CN121604968A (zh) | 2023-05-22 | 2026-03-03 | 萨那生物科技公司 | 递送胰岛细胞的方法及相关方法 |
| AU2024328949A1 (en) | 2023-08-23 | 2026-03-12 | Sana Biotechnology, Inc. | Modified cd47 proteins and their uses |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9301916D0 (sv) | 1993-06-03 | 1993-06-03 | Ab Astra | New peptides derivatives |
| TWI238827B (en) | 1995-12-21 | 2005-09-01 | Astrazeneca Ab | Prodrugs of thrombin inhibitors |
| SE9900070D0 (sv) * | 1999-01-13 | 1999-01-13 | Astra Ab | New use |
| SE523817C2 (sv) | 1999-02-05 | 2004-05-18 | Corline Systems Ab | Användning av ett koagulationsförebyggande ämne i samband med transplantation av insulinproducerande celler |
| US6462021B1 (en) | 2000-11-06 | 2002-10-08 | Astrazeneca Ab | Use of low molecular weight thrombin inhibitor |
| SE0200198D0 (sv) * | 2002-01-23 | 2002-01-23 | Astrazeneca Ab | New use |
-
2002
- 2002-01-23 SE SE0200198A patent/SE0200198D0/xx unknown
-
2003
- 2003-01-21 CN CNB038026740A patent/CN100430089C/zh not_active Expired - Fee Related
- 2003-01-21 NZ NZ533749A patent/NZ533749A/en unknown
- 2003-01-21 US US10/502,069 patent/US7045502B2/en not_active Expired - Fee Related
- 2003-01-21 CA CA002472241A patent/CA2472241A1/en not_active Abandoned
- 2003-01-21 IL IL16285303A patent/IL162853A0/xx unknown
- 2003-01-21 MX MXPA04007192A patent/MXPA04007192A/es unknown
- 2003-01-21 BR BR0306798-0A patent/BR0306798A/pt not_active IP Right Cessation
- 2003-01-21 EP EP03701203A patent/EP1469874A1/en not_active Withdrawn
- 2003-01-21 JP JP2003561625A patent/JP2005516035A/ja active Pending
- 2003-01-21 KR KR10-2004-7011228A patent/KR20040075096A/ko not_active Withdrawn
- 2003-01-21 WO PCT/SE2003/000087 patent/WO2003061682A1/en not_active Ceased
-
2004
- 2004-07-05 ZA ZA2004/05342A patent/ZA200405342B/en unknown
- 2004-08-20 NO NO20043483A patent/NO20043483L/no not_active Application Discontinuation
-
2006
- 2006-02-24 US US11/362,890 patent/US20060148720A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2472241A1 (en) | 2003-07-31 |
| US7045502B2 (en) | 2006-05-16 |
| EP1469874A1 (en) | 2004-10-27 |
| IL162853A0 (en) | 2005-11-20 |
| US20050090424A1 (en) | 2005-04-28 |
| WO2003061682A1 (en) | 2003-07-31 |
| NZ533749A (en) | 2006-02-24 |
| SE0200198D0 (sv) | 2002-01-23 |
| CN100430089C (zh) | 2008-11-05 |
| BR0306798A (pt) | 2004-12-07 |
| KR20040075096A (ko) | 2004-08-26 |
| NO20043483L (no) | 2004-08-20 |
| JP2005516035A (ja) | 2005-06-02 |
| US20060148720A1 (en) | 2006-07-06 |
| CN1729010A (zh) | 2006-02-01 |
| ZA200405342B (en) | 2005-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Nijhoff et al. | Glycemic stability through islet-after-kidney transplantation using an alemtuzumab-based induction regimen and long-term triple-maintenance immunosuppression | |
| US7045502B2 (en) | Use of melagatran for the manufacture of a medicament for the treatment of Type 1 diabetes mellitus | |
| CN109640959A (zh) | 靶向先天免疫系统以诱导长期耐受性及解决动脉粥样硬化中的巨噬细胞累积 | |
| KR100828807B1 (ko) | 새로운 용도의 덱스트란 설페이트 | |
| JP2013216675A (ja) | 細胞外マトリクスの分解の阻害 | |
| Waegell et al. | A420983, a novel, small molecule inhibitor of LCK prevents allograft rejection | |
| Yue et al. | Cutting edge of immune response and immunosuppressants in allogeneic and xenogeneic islet transplantation | |
| Vasanthan et al. | Periodontal treatment considerations for cell transplant and organ transplant patients. | |
| JP2021516052A (ja) | 胸腺組織に由来する制御性ｔ細胞を入手する方法および免疫系障害における細胞免疫療法としての前記細胞の使用 | |
| US7659249B2 (en) | Membrane-permeable NFAT inhibitory peptide | |
| RU2450052C2 (ru) | Способ получения бета-клеток поджелудочных желез кроликов и композиция для стимуляции выработки собственного инсулина у пациента | |
| Kenmochi et al. | Protection of mouse islet isografts from nonspecific inflammatory damage by recipient treatment with nicotinamide and 15-deoxyspergualin | |
| EP1392323B1 (en) | Use of a vitamin d3 analogue for the treatment of autoimmune diabetes | |
| CN102665703B (zh) | 在胰岛移植中作为佐剂的cxcr1/2抑制剂 | |
| US8048411B2 (en) | Co-transplantation of hepatic stellate cells and islet cells | |
| CN114762697B (zh) | 用于治疗糖尿病的药物及方法 | |
| AU2003202192A1 (en) | The use of melagatran for the manufacture of a medicament for the treatment of type 1 diabetes mellitus | |
| CN114762725B (zh) | 一种治疗糖尿病的方法 | |
| US20050255111A1 (en) | Use of an inhibitor or antagonist against tissue factor | |
| Yoshimatsu et al. | The impact of allogenic blood transfusion on the outcomes of total pancreatectomy with islet autotransplantation | |
| RU2758536C1 (ru) | Способ снижения воспалительной гиперактивации нейтрофилов | |
| Mattke | Targeting Toll-Like Receptor 4 Related Inflammation Using Small Molecule, TAK-242, to Attenuate Inflammatory Damage in Pancreatitis and Islet Transplantation | |
| Mineo et al. | Islet and pancreas transplantation | |
| WO2022143905A1 (zh) | 一种治疗糖尿病的药物及其方法 | |
| Harlan | Benefits and risks of solitary islet transplantation for type 1 diabetes using steroid-sparing immunosuppression |